Protein lin-28 homolog A Antibodies

Protein lin-28 homolog A (LIN28A)

RNA-binding protein which inhibits processing of pre-let- 7 miRNAs and regulates translation of mRNAs that control developmental timing, pluripotency and metabolism (PubMed:21247876). Appears to recognize a common structural G- quartet (G4) feature in its own miRNA and mRNA targets (Probable).

'Translational enhancer' that compels specific mRNAs to polysomes and increases the efficiency of protein synthesis. Its association with the translational machinery and target mRNAs results in an increased number of initiation events per molecule of mRNA and, indirectly, in mRNA stabilization.

Gene Information

Human
Gene Name:	LIN28A
Uniprot:	Q9H9Z2
Entrez:	79727

Family

Belongs to:
lin-28 family

Alternative Names

CSDD1; CSDD1lin-28A; FLJ12457; lin-28 homolog (C. elegans); lin-28 homolog A (C. elegans); LIN28; LIN-28; LIN28A; LIN-28A; LIN28RNA-binding protein LIN-28; Tex17; ZCCHC1; ZCCHC1protein lin-28 homolog A; Zinc finger CCHC domain-containing protein 1; zinc finger, CCHC domain containing 1

Molecular Weight

Mass (kDA):
22.743 kDA

Genomic Context

Human
Location:	1p36.11
Sequence:	1; NC_000001.11 (26410778..26429728)

Tissue Specificity

Expressed in embryonic stem cells, placenta and testis. Tends to be up-regulated in HER2-overexpressing breast tumors.

Subcellular Localizations

Cytoplasm. Rough endoplasmic reticulum. Cytoplasm, P-body. Cytoplasm, Stress granule. Nucleus, nucleolus. Predominantly cytoplasmic (PubMed:22118463). In the cytoplasm, localizes to peri-endoplasmic reticulum regions and detected in the microsomal fraction derived from rough endoplasmic reticulum (RER) following subcellular fractionation. May be bound to the cytosolic surface of RER on which ER-associated mRNAs are translated (By similarity). Shuttle from the nucleus to the cytoplasm requires RNA-binding (PubMed:17617744). Nucleolar localization is observed in 10-15% of the nuclei in different

Diseases

• Malignant Neoplasms
• Neoplasms
• Cell Transformation, Neoplastic
• Diabetes Mellitus
• Malignant Neoplasm Of Breast
• Neoplasm Invasiveness
• Mammary Neoplasms
• Insulin Sensitivity
• Neoplasm Metastasis
• Embryonal Carcinoma
• Malignant Tumor Of Colon
• Carcinoma

• Neoplasms, Glandular And Epithelial
• Myeloid Leukemia
• Pituitary Diseases
• Lymphoma
• Anaplasia
• Impaired Glucose Tolerance
• T-cell Lymphoma

Pathways

• Cell Cycle
• Menarche
• Translation
• Transport
• Organic Acid Transport
• Aging
• Embryo Development
• Cell Division
• Cell Morphogenesis Involved In Differentiation
• Invasive Growth
• Placenta Development
• Cell Morphogenesis
• Gonad Development

• Cell-cell Adhesion
• Endoderm Development
• Lipid Localization
• Secretory Pathway
• Cell Proliferation
• Cell Aging
• Cell Development

PTMs

• Acetylation

For details, visit:
bosterbio.com/bosterbio-gene-info-cards/LIN28A

Boster Bio - Best Uses Of The LIN28A Marker

The Protein homolog A of lin-28 (PLA) is recognized in a variety of biological tests by antibodies. These antibodies, monoclonal or polyclonal, are able to react with this molecule within a wide range of animal samples. Boster Bio developed LIN28A antibodies in mice and rabbits, two species that are recognized to express high levels of the molecule. PLLA inhibits pre-let-7 miRNA processing, which controls the transcription of mRNA. It is multifunctional and recognizes the G4 feature in its own targets.

LIN28A

When a tumor displays high levels of the LIN28A marker, it is considered to be a CSC. These cells are often characterized by a high tumor burden as well as a poor prognosis because of the fact that they typically contain both LIN28A or LIN28B. LIN28A and LIN28B attach to the terminal loop of let-7 and activate the terminal uridylyltransferase ZCCHC11 to polyuridylate let-7's pre-let-7. This causes a decrease in the let-7 synthesis as well as an increase in expression of oncogenic targets.

Clinical data suggests that LIN28A may be involved in the resistance of breast cancer cells against radiation. Numerous studies using GEM tumor models confirmed that LIN28AB is involved in mammalian carcinoma. These GEM cancer models demonstrate that cancer cells with inducible LIN28AB expression exhibit an aggressive growth rate and metastasis. For example, tumor sensitivity to radiation was increased due to the downregulation of LIN28A.

LIN28A is a tumor suppressor gene which suppresses the expression of let-7 in cancerous cells. It functions by binding prilet-7 in the nucleus, thereby preventing its cleavage through Microprocessor. It then directs polyuridylation of the pre-let-7 protein via an unidentified TUTase. After polyuridylation is complete, the protein is degraded.

The LIN28A marker, which regulates mRNA transcription is a very specific mRNA binding protein. The LIN28A marker is able to identify a variety of mRNAs. It is a crucial tool for researchers to investigate how mRNAs affect cellular development and function. Download the Boster Bio eBook, "Best uses of the LIN28A Marker" to know more about LIN28A.

A large sample of brain tumors was examined to determine which gene that expressed LIN28A was highly expressed in ETMR. Nine tumors with LIN28A were not ETMR positive. These findings suggest that the reactivation of LIN28A in cancer cells may cause a tumor to have high LIN28AB expression. Although there are limitations but there is a positive future for this gene.

The function of LIN28A in hypokinetic disorders isn't well understood. It is however believed to enhance protein synthesis and is crucial for the proliferation of neuronal precursor cells and maintenance. In vitro studies have shown that LIN28A is a key factor in determining the fate and fate of cells in gliogenesis. While this gene is essential in PD but its role in brain tumor development remains unclear. The most effective applications of this marker are currently being studied.

ZCCHC11

We will be discussing the many applications of the LIN28A mark in this article. This protein functions as a binding protein for mRNA. LIN28A is a protein that could be a useful biomarker for diagnostic purposes. It must be confirmed that the protein binds to an mRNA before being employed for ETMR.

LIN28A is a protein that has been found in both glia and neurons. It is implicated in synaptic plasticity since it is a key component in neuronal activity. In animal models, LIN28A is a key player in synaptic plasticity as well as neuronal differentiation. This protein is present in neurons labeled NeuN-positive and in glia cells with OLIG2 protein. Recent research has shown that it is highly expressed in the cortex and mice with GL.

LIN28A increases protein synthesis early brain development. It is also linked to neuronal precursor cells ' proliferation and maintenance. Previous studies have indicated that LIN28A is important in determining the fate of cells in glioneurogenesis. Its role in brain tumor formation is not yet understood. If you are interested in the best uses of the LIN28A marker, contact Boster Bio today.

Let-7

The axis LIN28A/LET-7 is involved in the resistance to radiation and other therapeutic agents in human cancer cells carrying K-RAS mutation. We will discuss the role of LIN28A/LET-7 in tumorigenesis, as well as the important role of LIN28A/LET-7 along with LIN28 in metastasis, cancer stem cells, radiation resistance, and resistance to chemotherapies, and radiation. This pathway could be targeted at the molecular level in order to provide therapeutic benefits for cancer patients.

Lin28A is a key component in tissue regeneration and repair. Expression of the protein promotes tissue repair and regeneration in young mice. The protein's translational enhancement results from let-7-dependent as well as independent functions. In human studies, LIN28A expression is required for the restoration of tissue and regeneration. It regulates the activity and phosphorylation levels of other metabolic enzymes.

The LIN28A/LIN28B-axis could play a role in the formation of CSCs. In a recent study metformin increased the expression of LIN28A in CSCs and reversed stemness in tumor cells which resulted in improved in vivo efficacy of the chemotherapeutic. However, further studies are needed to verify this theory.

Specific targeting of LIN28A is required for microRNA replacement therapy. New therapies that decrease LIN28AB expression or increase expression of let-7 in cancer cells may be promising. These novel therapeutics may be used in patients with cancer that expresses LIN28AB. These innovative therapies could ultimately improve the treatment outcomes of patients suffering from cancer that is metastatic or resistant to treatment.

LIN28A regulates self-renewal spermatogonial stem cell renewal in mammals. The protein is more compatible with LIN28B than the LIN28B marker and regulates self-renewal of the spermatogonia. A similar connection is observed for LIN28A and LIN28B in human cells.

According to research by the Daley laboratory and a phylogenetic tree the expression of the LIN28A/LIN28B gene has clinical significance in different types of cancer. Both gene sequences were examined using MEGA4/LINE284. Inducing LIN28a/LIN28B expression, increased the risk of developing tumors and also accelerated tumor development in ApcMin mice. The inducible expression of LIN28AB also improved the quality of mouse models of cancer.

Lin28a is only expressed in the testis of dairy goats. Its expression is regulated by oestrogen levels. The gene stimulates the growth of mouse SSCs. It also encourages the growth of testis-derived embryogonial stem cells. This suggests that the LIN28A gene may be a useful marker for dairy goat stem cells from spermatogonial sources.

GmGSCsI-SB-Lin28a cells increase the expression of LIN28A at the protein level. Interestingly, LIN28A stimulates the proliferation of GmGSC-SB cells. The brain also expresses the LIN28A gene, which suggests its role in cancer. These studies were helpful in understanding how GmGSC–SB cells differ and grow.